李海涛

个人简介
科研项目
学术论文
获奖
专利
承担教学
研究生培养

姓名：李海涛	性别：
民族：	年龄：
最高学历：	学位：
教育背景: 　　1998.9-2002.7 山东农业大学, 植物保护 (植物检疫方向), 大学本科　　2002.9-2005.7 山东农业大学, 农药学, 硕士研究生　　2006.1-2010.2 香港大学, 食品科学, 博士研究生　　工作经历: 　　2010.2-2014.7 美国明尼苏达大学荷梅尔癌症研究所, 肿瘤预防, 博士后　　2014.8-至今江南大学食品学院, 校聘教授　　研究领域: 　　肿瘤及常见慢性疾病高风险人群的膳食干预及功能性食品研发。已在肿瘤学, 药理学　　及食品科学研究领域发表SCI论文29篇，影响因子总和145.2，他引次数共计286次。

　　1. Li H, Zhu F, Boardman LA, Wang L, Oi N, Liu K, Li X, Fu Yang, Limburg PJ, Bode AM, Dong Z. Aspirin prevents colorectal cancer by normalizing EGFR expression. EBioMedicine. 2015; 2(5): 447-55.

　　2. Li H, Liu K, Boardman LA, Zhao Y, Wang L, Sheng Y, Oi N, Limburg PJ, Bode AM, Dong Z. Circulating prostaglandin biosynthesis in colorectal cancer and potential clinical significance. EBioMedicine. 2015; 2(2): 165-71.

　　3. Li H, Zhu F, Chen H, ChengKW, Zykova T, Oi N, Lubet RA, Bode AM, Wang M, Dong Z. 6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1. Cancer Res. 2014;74(1): 243-52. IF: 9.284

　　4. Sheng Y, Li W, Zhu F, Liu K, Chen H, Yao K, Reddy K, Lim do Y, Oi N, Li H, Peng C, Ma WY, Bode AM, Dong Z, Dong Z. 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer. J Biol Chem. 2014; 289(41): 28192-201. IF: 4.600

　　5. Yang G, Fu Y, Malakhova M, Kurinov I, Zhu F, Yao K, Li H, Chen H, Li W, Lim do Y, Sheng Y, Bode AM, Dong Z, Dong Z. Caffeic acid directly targets ERK1/2 to attenuate solar UV-induced skin carcinogenesis. Cancer Prev Res (Phila).2014;7(10):1056-66. IF: 5.269

　　6. Yao K, Chen H, Liu K, Langfald A, Yang G, Zhang Y, Yu DH, Kim MO, Lee MH, Li H, Bae KB, Kim HG, Ma WY, Bode AM, Dong Z, Dong Z. Kaempferol targets RSK2 and MSK1 to suppress UV radiation-induced skin cancer. Cancer Prev Res (Phila).2014;7(9):958-67. IF: 5.269

　　7. Fu Y, Yang G, Zhu F, Peng C, Li W, Li H, Kim HG, Bode AM,Dong Z, Dong Z. Antioxidants decrease the apoptotic effect of 5-Fu in coloncancer by regulating Src- dependent caspase-7 phosphorylation. Cell Death &Disease. 2014; 5: e983. IF: 5.177

　　8. Yao K, Chen H, Lee MH, Li H, Ma W, Peng C, Song NR, Lee KW, Bode AM, Dong Z, Dong Z. Licochalcone A, a natural inhibitor of c-Jun N-terminal kinase1. Cancer Prev Res (Phila). 2014; 7(1): 139-49. IF: 5.269

　　9. Xie H, Lee MH, Zhu F, Reddy K, Peng C, Li Y, Lim DY, Kim DJ, LiX,Kang S, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z. Identificationof an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res.2013; 73(2):716-24. IF: 9.284

　　10. Xie H, LeeMH, Zhu F, Reddy K, Huang Z, Kim DJ, Li Y, Peng C, Lim doY, Kang S, Jung SK, LiX, Li H, Ma W, Lubet RA, Ding J, Bode AM, Dong Z. Discovery of thenovel mTOR inhibitor and its antitumor activities in vitro and invivo. Mol Cancer Ther. 2013; 12(6): 950-8. IF: 6.107

　　11. Li H, Zhu F, Sun Y, Li B, Oi N, Chen H, Lubet RA, Bode AM, Dong Z. selec dietary phytochemicals function as inhibitors of COX-1 but not COX-2. PLoS One. 2013; 8(10): e76452. IF: 3.534

　　12. Xie H, ZhuF, Huang Z, Lee MH, Kim DJ, Li X, Lim DY, Jung SK, Kang S, Li H, ReddyK, Wang L, Ma W, Lubet RA, Bode AM, Dong Z. Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis.2012; 33(9): 1814-21. IF: 5.266

　　13. Li X, Li H，Li S, Zhu F, Lubet RA, Bode AM, Dong Z. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B. Carcinogenesis. 2012; 33(12): 2548-57. IF: 5.266 (共同第一作者)

　　14. Chen H, YaoK, Nadas J, Bode AM, Malakhova M, Oi N, Li H, Lubet RA, Dong Z. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One. 2012; 7(5): e38261. IF: 3.534

　　15. Li J, Mottamal M, Li H, Liu K, Zhu F, Cho YY, Sosa CP, Zhou K, Bowden GT, Bode AM, Dong Z. Quercetin-3-methyl ether suppresses transformation by targeting ERKs in mouse epidermal JB6 P+ cells. Carcinogenesis. 2012; 33(2): 459-65. IF: 5.266

　　16.Ye CG, WuWK, Yeung JH, Li H, Li ZJ, Wong CC, Ren SX, Zhang L, Fung KP, Cho CH. Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1expression. Cancer Lett. 2011; 304(2): 90-6. IF: 5.016

　　17. Li ZJ, WuWK, Yu L, Ng SM, Li H, Wong CM, Wu YC, Zhang L, Ren SX, Chan KM, Cho CH. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J Control Release. 2010;148(3): 292-302. IF: 7.261

　　18. Li H, Wu WK, Zheng ZP, Yu L, Li ZJ, Cho CH*, Wang M. 3,3',4,5,5'-Pentahydroxy-trans-stilbene,a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress. Eur J Pharmacol. 2010; 637(1-3):55-61. IF: 2.684

　　19. Li H, Wu WK, Li ZJ, Wong CM, Ye CG, Cho CH and Wang M. 2,3′,4,4′,5′-Pentamethoxy-trans-stilbene,a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in the AOM/DSS model. Br J Pharmacol. 2010; 160(6): 1352-61. IF: 4.99

　　20. Wu WK, Cho CH, Lee CW, Wu YC, Yu L, Li ZJ, Wong CM, Li H, Zhang L, Ren SX, Che CT, Yu J and Sung JY. Macroautophagy and ERK phosphorylation counteract the anti-proliferative effect of proteasome inhibitor in gastric cancer cells. Autophagy. 2010; 6(2): 228-38. IF: 11.423

　　21. Wu WK, Sung JY, To KF, Yu L, Li H, Li ZJ, Chu KM, Yu J and Cho CH. The host defense peptide LL-37 activates the tumor-suppressing bone morphogeneticprotein signaling via inhibition of proteasome in gastric cancer cells. J. Cell Physiol. 2010; 223(1): 178-86. IF: 3.874

　　22. Chao J, Li H, Cheng, KW, Yu MS, Chang RCC and Wang M. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J. Nutrit. Biochem. 2010; 21(6):482-9. IF: 4.592

　　23. Li H, Wu KK, Zheng ZP, Che CT, Yu L, Li ZJ, Wu YC, Cheng KW, Yu J, Cho CH and Wang M. 2,3′,4,4′,5′-Pentamethoxy-trans-stilbene, a resveratrol derivative, is a potent inducer of apoptosis in colon cancer cells via targeting microtubules. Biochem Pharmacol. 2009; 78(9): 1224-32. IF: 4.65

　　24. Yu L, Wu WK, Li ZJ, Li H, Wu YC, Cho CH. Prostaglandin E2 promotes cell proliferation via activation of PKC/extracellular signal regulated kinase pathway dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Int J Cancer. 2009; 125(11): 2540-2546. IF: 5.007

　　25. Wu WK, Volta V, Cho CH, Wu YC, Li H,Yu L, Li ZJ, Sung JJ. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells. Biochem Biophys Res Commun. 2009; 386 (4): 598-601. IF: 2.281

　　26. Yu L, Wu WK, Li ZJ, Liu QC, Li H, WuYC, Cho CH. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and SC236 via inhibiting P-glycoprotein activity. Mol Pharmacol.2009; 75(6): 1364-73. IF: 4.12

　　27. Wu YC, Wu WK, Li Y, Yu L, Li ZJ, Wong CC, Li H, Sung JJ, Cho CH. Inhibition of macroautophagy by bafilomycinA(1) lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun.2009;382 (2): 451-456. IF: 2.281

　　28. Wu WK, Sung JJ, Wu YC, Li H, Yu L,Li ZJ, Cho CH. Inhibition of cyclooxygenase-1 lowers proliferation and induces macroautophagy in colon cancer cells. Biochem Biophys Res Commun. 2009;382 (1): 79-84. IF: 2.281

　　29. Yu L, Wu WK, Li ZJ, Wong HP, Tai EK, Li H, Wu YC, Cho CH. E-series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cellcarcinoma. J Pharmacol Exp Ther. 2008; 327 (1): 258-267. IF: 3.855

　　30. Zheng ZP, Cheng KW, To JT, Li H,Wang M. Isolation of tyrosinase inhibitors from Artocarpus heterophyllus and use of its extract as antibrowning agent. Mol Nutr Food Res. 2008; 52 (12):1530-1538. IF: 4.909

　　31. Li H, Cheng KW, Cho CH, He Z, Wang M. Oxyresveratrol as an antibrowning agent for cloudy apple juices and fresh-cut apples. J Agric Food Chem. 2007;55(7): 2604-2610. IF: 3.107